Fresenius Q1/22 Results
Financial Results
Q1/22 Results
Fresenius with solid start to 2022 despite macroeconomic challenges
-
Fresenius Medical Care in line with its expectations countering significant headwinds
-
Fresenius Kabi’s solid financial performance based on strong Emerging Markets growth
-
Fresenius Helios’ strong performance driven by growing admissions in Germany and Spain
-
Fresenius Vamed with continued progress towards normal operations, very good performance in the service business
-
Ongoing headwinds from cost inflation and supply chain challenges, with uncertainty and volatility fueled by the Ukraine war
-
Guidance for 2022 confirmed
-
Fresenius appoints Sara Hennicken as Chief Financial Officer – Rachel Empey to leave company at own request
-
Dr. Carla Kriwet to succeed Rice Powell on January 1, 2023, as Chief Executive Officer of Fresenius Medical Care and member of the Fresenius Management Board
Selected Key Figures Q1/2022
SALES
€ 9720 m
+ 5% 1
Q1/21: €8,984 m
EBIT 2
€ 996 m
-5% 1
Q1/21: €1,009 m
NET INCOME 2, 3
€ 462 m
+3% 1
Q1/21: €436 m
EARNINGS PER SHARE 2, 3
€ 0.83 m
+3% 1
Q1/21: €0.78
1 In constant currency
2 Before special items
3 Net income attributable to shareholders of Fresenius SE & Co. KGaA
Sales by business segment
| € in millions | Q1/22 | Q1/21 | Change | Organic sales growth | Currency translation effects | Acquisitions | Divestitures | % of total sales1 |
|---|---|---|---|---|---|---|---|---|
Fresenius Medical Care | 4,548 | 4,210 | 8% | 2% | 5% | 1% | 0% | 47% |
Fresenius Kabi | 1,847 | 1,761 | 5% | 1% | 4% | 0% | 0% | 19% |
Fresenius Helios | 2,931 | 2,649 | 11% | 8% | 0% | 3% | 0% | 30% |
Fresenius Vamed | 513 | 477 | 8% | 7% | 1% | 0% | 0% | 4% |
Total | 9,720 | 8,984 | 8% | 3% | 3% | 2% | 0% | 100% |
-
1 Related to the respective external sales of the business segments. Consolidation effects and corporate entities are not taken into account. Therefore, aggregation to total Group sales is not possible.